Table 1.
Basic characteristics of the included studies in the present meta-analysis.
| First author | Year | Country | Total cases | Female(%) | Age | Histological types | Stage | Smoking history | PD-L1 Expression | ECOG PS | Follow up duration median or up to(M) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NSCC | SCC | III | IV | current | former | never | positive | negative | unknown | 0 | ≥1 | ||||||||
| Iijima, Y. | 2017 | Japan | 14.00 | 5 (36) | 66 | 10 | 4 | 0 | 14 | 0 | 10 | 4 | 2 | 0 | 12 | 10 | 4 | 10 | |
| Gandara, D. R (1) | 2018 | US | 144.00 | 51 (35) | 62 | 95 | 49 | advanced | 25 | 92 | 27 | NA | NA | NA | 48 | 96 | 27 | ||
| Gandara, D. R (2) | 425.00 | 164 (39) | 63 | 313 | 112 | advanced | 59 | 282 | 84 | NA | NA | NA | 155 | 270 | 27 | ||||
| Goldberg, S. B | 2018 | US | 49.00 | 31 (63) | 67 | 47 | 2 | advanced | 1 | 43 | 5 | NA | NA | NA | NA | NA | 20 | ||
| Raja, R (1) | 2018 | US | 28.00 | 8 (29) | 62 | 10 | 18 | 3 | 25 | 22 | 6 | 13 | 13 | 2 | 10 | 18 | 15 | ||
| Raja, R (2) | 72.00 | 30 (42) | 61 | 57 | 15 | 16 | 56 | 59 | 13 | 58 | 11 | 3 | 27 | 45 | 9 | ||||
| Anagnostou, V. | 2019 | US | 24.00 | 12 (50) | 64 | 16 | 8 | 0 | 24 | 3 | 18 | 3 | NA | NA | NA | NA | NA | 12.7 | |
| Guibert, N | 2019 | French | 97.00 | 37 (38) | NA | 76 | 21 | 11 | 86 | 22 | 63 | 7 | 35 | 40 | 22 | 87(0-2) | 4(≥2) | 24 | |
| Chen, Y. | 2020 | China | 22.00 | 5 (23) | 62 | 10 | 12 | 5 | 17 | 15 | 7 | 11 | 4 | 7 | NA | NA | 15 | ||
| Jia, Q | 2020 | China | 9.00 | 1 (11) | 65 | 6 | 3 | 0 | 9 | 0 | 8 | 1 | NA | NA | NA | NA | NA | 10 | |
| Nabet, B. Y. | 2020 | US | 99.00 | 51 (52) | 65 | 85 | 14 | advanced | 13 | 64 | 22 | 58 | 24 | 17 | NA | NA | 50 | ||
| Zulato, E | 2020 | Italy | 34.00 | NA | 68 | NA | NA | advanced | NA | NA | NA | NA | NA | NA | NA | NA | 13.1 | ||
| First author | Year | Drugs (number) | Previous therapy lines | Sample | Detection method | Platform | Detection time (weeks) | Most mutated genes | |||||||||||
| 0-1 | >1 | ||||||||||||||||||
| Iijima, Y. | 2017 | Nivolumab (14) | NA | plasma | NGS | Ion Proton | baseline, 1, 2, 4, 6,8 | TP53 | |||||||||||
| Gandara, D. R (1) | 2018 | Atezolizumab (144) | 93 | 51 | plasma | NGS | Illumina HiSeq 4000 | baseline | KRAS | ||||||||||
| Gandara, D. R (2) | Atezolizumab (425) | 320 | 105 | plasma | NGS | Illumina HiSeq 4000 | baseline | EGFR | |||||||||||
| Goldberg, S. B | 2018 | anti–PD-1 (36); anti–PD-L1 (2) anti-PD-L1+ID01 inhibitor (2) anti-CTLA-4+anti PD-L1 (7) anti-CTLA-4+anti PD-1 (2) |
40 | 9 | plasma | NGS | Illumina HiSeq 2500 | baseline, 2 | KRAS | ||||||||||
| Raja, R (1) | 2018 | Durvalumab (28) | 11 | 17 | plasma | NGS | Guardant360 | baseline, 6 | TP53 | ||||||||||
| Raja, R (2) | Durvalumab (72) | 0 | 72 | plasma | NGS | Guardant360 | baseline, 6 | TP53 | |||||||||||
| Anagnostou, V. | 2019 | Nivolumab (14); Pembrolizumab (5) Nivolumab+anti-LAG3 (1) Nivolumab+Ipilimumab (1) Pembrolizumab+chemotherapy (3) |
NA | plasma | NGS | Illumina HiSeq 2500 | baseline, 4 or 8, the time of disease progression |
KRAS | |||||||||||
| Guibert, N | 2019 | Nivolumab (90); Pembrolizumab (7) | 57 | 40 | plasma | NGS | Illumina NextSeq 500 | baseline, 4 | KRAS | ||||||||||
| Chen, Y. | 2020 | Camrelizumab + Apatinib (22) | 14 | 8 | plasma | NGS | Illumina Novaseq 6000 | baseline | TP53 | ||||||||||
| Jia, Q | 2020 | Durvalumab (4) Tremelimumab+Durvalumab (5) |
NA | plasma | NGS | Illumina Novaseq 6000 | baseline, 8 | TTN | |||||||||||
| Nabet, B. Y. | 2020 | anti–PD-L1 (1); anti–PD-1 (31) anti–PD-1+anti–CTLA-4 (5) anti–PD-1+Chemotherapy (5) |
41 | 58 | plasma | NGS | Illumina HiSeq4000 | baseline, the time of the second infusion |
TP53 | ||||||||||
| Zulato, E | 2020 | Nivolumab (12) Pembrolizumab (18) Atezolizumab (4) |
NA | plasma | ddPCR | Bio-Rad QX200 | baseline, first radiological restaging |
KRAS | |||||||||||
NSCC, Non-squamous cell carcinoma; SCC, Squamous cell carcinoma; NA, not applicable; NGS, Next-generation sequencing; ddPCR, Droplet Digital PCR; M, months.